Switzerland's Ferring Pharma to build $32M discovery, development and manufacturing center at HQ
Expanding its global headquarters in Switzerland, Ferring Pharmaceuticals is investing 30 million Swiss francs (roughly $32 million) in a new biotech center.
In addition to manufacturing biologics (including Rekovelle, the latest of the company’s many fertility treatments), the new facility will have discovery and development capabilities for monoclonal antibodies.
Ferring, a specialty pharma with a long history of making drugs for women and their babies, already operate a number production facilities around the globe, with production facilities from Argentina to Denmark to India.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.